Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance)
Yuan C, Sato K, Hollis BW, Zhang S, Niedzwiecki D, Ou FS, Chang IW, O'Neil BH, Innocenti F, Lenz HJ, Blanke CD, Goldberg RM, Venook AP, Mayer RJ, Fuchs CS, Meyerhardt JA, Ng K
Clinical cancer research : an official journal of the American Association for Cancer Research · 54 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Organización sin fines de lucro
- Alliance for Clinical Trials in Oncology Foundation
- Gobierno
- National Institutes of Health
- Gobierno
- National Cancer Institute
- Gobierno
- National Institute of General Medical Sciences
- Gobierno
- NCI NIH HHS
- Gobierno
- NIH
- Organización sin fines de lucro
- Alliance for Clinical Trials in OncologyFoundation
- Gobierno
- NIGMS NIH HHS
- Subvenciones
- Alliance for Clinical Trials in Oncology Foundation (P50CA127003); National Cancer Institute (K07CA148894); National Cancer Institute (R01CA118553); National Institute of General Medical Sciences (U54-GM-104942); National Cancer Institute (U10 CA180821); National Cancer Institute (U10-CA180888); National Cancer Institute (UG1 CA233180); National Cancer Institute (U24 CA196171); National Cancer Institute (U10CA180830); National Cancer Institute (U10 CA180867); Alliance for Clinical Trials in Oncology Foundation (UG1CA189858); National Cancer Institute (U10CA180795); Alliance for Clinical Trials in Oncology Foundation (U10CA180826); Alliance for Clinical Trials in Oncology Foundation (U10CA180830); National Cancer Institute (U10CA180838); National Cancer Institute (R01 CA205406); National Cancer Institute (U10-CA180882); Alliance for Clinical Trials in Oncology Foundation (R01CA118553); Alliance for Clinical Trials in Oncology Foundation (U10CA180888); Alliance for Clinical Trials in Oncology Foundation (U24CA196171); National Cancer Institute (P50-CA127003); National Cancer Institute (UG1 CA189974); Alliance for Clinical Trials in Oncology Foundation (U10CA180795); National Cancer Institute (U10 CA180826); National Cancer Institute (UG1CA189858); Alliance for Clinical Trials in Oncology Foundation (K07CA148894); Alliance for Clinical Trials in Oncology Foundation (U10CA180838); Alliance for Clinical Trials in Oncology Foundation (R01CA205406); Alliance for Clinical Trials in Oncology Foundation (U10CA180867); National Institutes of Health (U10CA180 882); National Institutes of Health (U10-CA180821)
Según 8 financiadores declarados.
Publicación
- Publicado
- 2019-09-23 · Clin Cancer Res · vol. 25 · número 24 · págs. 7497–7505
- Editorial
- American Association for Cancer Research
- Citado
- 66 citas · más que el 96% de estudios similares · 4.7× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 47 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Vitamin D Research Studies · Bone health and treatments · Estrogen and related hormone effects
- Palabras clave
- Medicine, Internal medicine, Colorectal cancer, Hazard ratio, Proportional hazards model, Oncology, Vitamin D and neurology, Cancer, Chemotherapy, Progression-free survival, Prospective cohort study, Confidence interval, Gastroenterology
- MeSH
- humans, colorectal neoplasms, neoplasm metastasis, vitamins, vitamin d, prognosis, survival rate, prospective studies, female, male
17 autores
- Chen Yuan🇺🇸 · autor de correspondenciaDana-Farber Cancer Institute
- Kaori Sato🇺🇸Dana-Farber Cancer Institute
- Bruce W. Hollis🇺🇸Medical University of South Carolina
- Sui Zhang🇺🇸Dana-Farber Cancer Institute
- Donna Niedzwiecki🇺🇸Duke University
- Fang‐Shu Ou🇺🇸Mayo Clinic; Mayo Clinic in Arizona; Mayo Clinic in Florida
- I-Wen Chang🇺🇸Southeast Clinical Oncology Research Consortium
- Bert H. O’Neil🇺🇸Indiana University – Purdue University Indianapolis
- Federico Innocenti🇺🇸University of North Carolina at Chapel Hill
- Heinz‐Josef Lenz🇺🇸University of Southern California; USC Norris Comprehensive Cancer Center
- Charles David Blanke🇺🇸Oregon Health & Science University
- Richard M. Goldberg🇺🇸West Virginia University
- Alan Paul Venook🇺🇸University of California, San Francisco
- Robert J. Mayer🇺🇸Dana-Farber Cancer Institute
- Charles S. Fuchs🇺🇸Smilow Cancer Hospital
- Jeffrey A. Meyerhardt🇺🇸Dana-Farber Cancer Institute
- Kimmie Ng🇺🇸Dana-Farber Cancer Institute
Resumen
El texto original del estudio, en el idioma en que se publicó.
Purpose
Previous studies have suggested that higher circulating 25-hydroxyvitamin D [25(OH)D] levels are associated with decreased colorectal cancer risk and improved survival. However, the influence of vitamin D status on disease progression and patient survival remains largely unknown for patients with advanced or metastatic colorectal cancer.
Experimental design
We prospectively collected blood samples in 1,041 patients with previously untreated advanced or metastatic colorectal cancer participating in a randomized phase III clinical trial of first-line chemotherapy plus biologic therapy. We examined the association of baseline plasma 25(OH)D levels with overall survival (OS) and progression-free survival (PFS). Cox proportional hazards models were used to calculate hazard ratios (HRs) and confidence intervals (CIs), adjusted for prognostic factors and confounders.
Results
At study entry, 63% of patients were vitamin D deficient (P trend = 0.0009 and 0.03, respectively). Compared with patients in the bottom quintile of 25(OH)D (≤10.8 ng/mL), those in the top quintile (≥24.1 ng/mL) had a multivariable-adjusted HR of 0.66 (95% CI, 0.53-0.83) for OS and 0.81 (95% CI, 0.66-1.00) for PFS. The improved survival associated with higher 25(OH)D levels was consistent across patient subgroups of prognostic patient and tumor characteristics.
Conclusions
In this large cohort of patients with advanced or metastatic colorectal cancer, higher plasma 25(OH)D levels were associated with improved OS and PFS. Clinical trials assessing the benefit of vitamin D supplementation in patients with colorectal cancer are warranted.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.